PL3359189T3 - Humanizowane przeciwciała anty-psa (5a10) - Google Patents
Humanizowane przeciwciała anty-psa (5a10)Info
- Publication number
- PL3359189T3 PL3359189T3 PL16778330T PL16778330T PL3359189T3 PL 3359189 T3 PL3359189 T3 PL 3359189T3 PL 16778330 T PL16778330 T PL 16778330T PL 16778330 T PL16778330 T PL 16778330T PL 3359189 T3 PL3359189 T3 PL 3359189T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- humanized anti
- anti psa
- psa
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1517550.8A GB201517550D0 (en) | 2015-10-05 | 2015-10-05 | Antibody polypeptides and uses thereof |
GBGB1519105.9A GB201519105D0 (en) | 2015-10-29 | 2015-10-29 | Antibody polypeptides and uses thereof |
EP16778330.7A EP3359189B1 (en) | 2015-10-05 | 2016-10-04 | Humanized anti psa (5a10) antibodies |
PCT/EP2016/073684 WO2017060247A1 (en) | 2015-10-05 | 2016-10-04 | Humanized anti psa (5a10) antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3359189T3 true PL3359189T3 (pl) | 2021-12-20 |
Family
ID=57113327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16778330T PL3359189T3 (pl) | 2015-10-05 | 2016-10-04 | Humanizowane przeciwciała anty-psa (5a10) |
Country Status (19)
Country | Link |
---|---|
US (2) | US11332543B2 (pl) |
EP (2) | EP3359189B1 (pl) |
JP (1) | JP6916797B2 (pl) |
KR (1) | KR20180053756A (pl) |
CN (1) | CN108136013B (pl) |
AU (1) | AU2016334715B2 (pl) |
BR (1) | BR112018006820A2 (pl) |
CA (1) | CA2998818A1 (pl) |
DK (1) | DK3359189T3 (pl) |
ES (1) | ES2880682T3 (pl) |
HK (1) | HK1258674A1 (pl) |
IL (1) | IL258189B2 (pl) |
LT (1) | LT3359189T (pl) |
MX (1) | MX2018004071A (pl) |
PL (1) | PL3359189T3 (pl) |
PT (1) | PT3359189T (pl) |
RU (1) | RU2753677C2 (pl) |
WO (1) | WO2017060247A1 (pl) |
ZA (1) | ZA201802019B (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3052639A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
AU2021212659A1 (en) | 2020-01-28 | 2022-08-04 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
FI20002127A0 (fi) * | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
ATE425186T1 (de) * | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
JP2010004895A (ja) | 2009-10-13 | 2010-01-14 | Hiroshima Univ | ヒト化ニワトリ抗体の製造方法 |
KR102362358B1 (ko) * | 2011-10-28 | 2022-02-15 | 프레닥스 에이비 | 치료제 및 이의 용도 |
RU2537263C2 (ru) | 2012-10-22 | 2014-12-27 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" | Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты) |
GB2520353A (en) | 2013-11-19 | 2015-05-20 | Fredax Ab | Antibody polypeptides and uses thereof |
MY192513A (en) * | 2014-03-28 | 2022-08-24 | Opko Diagnostics Llc | Compositions and methods related to diagnosis of prostate cancer |
-
2016
- 2016-10-04 BR BR112018006820A patent/BR112018006820A2/pt active Search and Examination
- 2016-10-04 PL PL16778330T patent/PL3359189T3/pl unknown
- 2016-10-04 LT LTEPPCT/EP2016/073684T patent/LT3359189T/lt unknown
- 2016-10-04 JP JP2018536343A patent/JP6916797B2/ja active Active
- 2016-10-04 CA CA2998818A patent/CA2998818A1/en active Pending
- 2016-10-04 WO PCT/EP2016/073684 patent/WO2017060247A1/en active Application Filing
- 2016-10-04 IL IL258189A patent/IL258189B2/en unknown
- 2016-10-04 RU RU2018115734A patent/RU2753677C2/ru active
- 2016-10-04 MX MX2018004071A patent/MX2018004071A/es unknown
- 2016-10-04 AU AU2016334715A patent/AU2016334715B2/en active Active
- 2016-10-04 KR KR1020187012299A patent/KR20180053756A/ko not_active Application Discontinuation
- 2016-10-04 US US15/761,260 patent/US11332543B2/en active Active
- 2016-10-04 DK DK16778330.7T patent/DK3359189T3/da active
- 2016-10-04 PT PT167783307T patent/PT3359189T/pt unknown
- 2016-10-04 EP EP16778330.7A patent/EP3359189B1/en active Active
- 2016-10-04 CN CN201680059166.8A patent/CN108136013B/zh active Active
- 2016-10-04 EP EP21173910.7A patent/EP3922265A1/en not_active Withdrawn
- 2016-10-04 ES ES16778330T patent/ES2880682T3/es active Active
-
2018
- 2018-03-27 ZA ZA2018/02019A patent/ZA201802019B/en unknown
-
2019
- 2019-01-21 HK HK19101041.6A patent/HK1258674A1/zh unknown
-
2022
- 2022-04-11 US US17/717,254 patent/US20220242969A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
LT3359189T (lt) | 2021-07-26 |
AU2016334715A1 (en) | 2018-04-12 |
JP2018531045A (ja) | 2018-10-25 |
IL258189B (en) | 2022-11-01 |
ES2880682T3 (es) | 2021-11-25 |
DK3359189T3 (da) | 2021-07-05 |
US20220242969A1 (en) | 2022-08-04 |
BR112018006820A2 (pt) | 2018-10-23 |
JP6916797B2 (ja) | 2021-08-11 |
KR20180053756A (ko) | 2018-05-23 |
RU2753677C2 (ru) | 2021-08-19 |
CA2998818A1 (en) | 2017-04-13 |
RU2018115734A (ru) | 2019-11-07 |
WO2017060247A1 (en) | 2017-04-13 |
AU2016334715B2 (en) | 2023-02-02 |
IL258189A (en) | 2018-05-31 |
PT3359189T (pt) | 2021-07-19 |
RU2018115734A3 (pl) | 2020-03-27 |
EP3359189B1 (en) | 2021-06-23 |
CN108136013A (zh) | 2018-06-08 |
CN108136013B (zh) | 2023-04-18 |
HK1258674A1 (zh) | 2019-11-15 |
EP3922265A1 (en) | 2021-12-15 |
EP3359189A1 (en) | 2018-08-15 |
ZA201802019B (en) | 2021-09-29 |
US20180273634A1 (en) | 2018-09-27 |
MX2018004071A (es) | 2018-11-09 |
US11332543B2 (en) | 2022-05-17 |
IL258189B2 (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288649A (en) | Human antibodies against tau | |
ZA201803874B (en) | Humanized anti-cd73 antibodies | |
HK1257164A1 (zh) | 新型抗pd-l1抗體 | |
IL255727A (en) | Novel anti-pd-l1 antibodies | |
PL3519437T3 (pl) | Przeciwciała dwuswoiste przeciwko p95HER2 | |
IL253909A0 (en) | Humanized *anti–muc1 antibodies | |
HK1258375A1 (zh) | 人源化抗-cll-1抗體 | |
IL247277A0 (en) | Monoclonal antibodies against Ebola | |
EP3294766C0 (en) | HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3 | |
IL256579A (en) | Human antibodies | |
IL248402A0 (en) | Humanized antibodies against ceacam1 | |
IL262776A (en) | Human anti-il-1r3 antibodies | |
PT3101131T (pt) | Anticorpo antitranstirretina humanizado | |
IL265016B (en) | A method for purifying antibodies | |
EP3131581A4 (en) | Humanized anti-tf-antigen antibodies | |
EP3490601A4 (en) | MONOCLONAL ANTI-ANNEXIN A2 ANTIBODIES | |
PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
HK1258674A1 (zh) | 人源化抗 psa 的 5a10 抗體 | |
EP3362093A4 (en) | MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE | |
GB201511196D0 (en) | Monoclonal antibodies |